Division of Becton Dickinson & Co.
Latest From Lutonix Inc.
Christopher Barry, a former VP of R&D at Bard subsidiary Lutonix, pleaded guilty to one count of theft of trade secrets. He now faces up to two and a half years in prison.
The agency’s Circulatory System Devices Panel will meet June 12 to consider Bard’s PMA, supported by data from Levant 2, a 476-patient randomized non-inferiority trial comparing Lutonix to a standard peripheral balloon catheter for the treatment of stenosis of the femoropopliteal arteries.
Six-month data from the rigorous Levant 2 trial, presented at the TCT conference in San Francisco, show peripheral angioplasty with Bard’s Lutonix paclitaxel-coated balloon reduces restenosis compared with regular balloon angioplasty. The findings give the company an edge in the race to be the first on the U.S. market with a drug-coated peripheral angioplasty balloon.
Data on Medtronic’s CoreValve transcatheter aortic valve replacement device will headline this year’s Transcatheter Cardiovascular Therapeutics conference, joined by data on biodegradable drug-eluting stents, as well as drug-coated balloon results, in the late-breaking trial sessions.
- Implantable Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Becton Dickinson & Co.
- Senior Management
Chris Barry, VP, R&D
Leslie Trigg, EVP, Mktg. & Commercialization Strategy
- Contact Info
Phone: (763) 445-2352
7351 Kirkwood Ln. N.
Maple Grove, MN 55369
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.